Supplementary Table 4. Global inconsistency assessment across outcomes

Outcomes	Chi-square	*P* value
fibrosis improvement at least one stage without steatohepatitis worsening	n.a	n.a
steatohepatitis resolution without fibrosis worsening	n.a	n.a
relative change from baseline in liver fat content	0.00	0.995
absolute change from baseline in liver fat content	n.a	n.a
ALT	0.08	0.776
AST	2.25	0.134
body weight	n.a	n.a
triglyceride	n.a	n.a
LDL-C	n.a	n.a
HDL-C	n.a	n.a
total cholesterol	n.a	n.a
HbA1c	n.a	n.a
fasting blood glucose	n.a	n.a
ELF score	0.03	0.874
PRO-C3	n.a	n.a
LSM-VCTE	n.a	n.a
Any adverse events during treatment	2.46	0.117
discontinuation due to adverse events	0.17	0.680
Serious adverse events	0.00	0.986
nausea	2.84	0.092
diarrhea	0.02	0.893
vomiting	2.77	0.096
Cardiovascular events	n.a	n.a

Note: n.a., not applicable due to insufficient indirect evidence for inconsistency assessment. LDL-C: low density lipoprotein-cholesterol; HDL-C: high density lipoprotein-cholesterol; ELF: enhanced liver fibrosis; PRO-C3: N-terminal type III collagen propeptide; LSM-VCTE: liver stiffness measurement assessed by vibration controlled transient elastography.